| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/TP.0B013E3181D21E7F |
| P698 | PubMed publication ID | 20110854 |
| P50 | author | Stanley C Jordan | Q96350303 |
| P2093 | author name string | Kai Cao | |
| Alice Peng | |||
| Mieko Toyoda | |||
| Nancy L Reinsmoen | |||
| Ashley A Vo | |||
| Chih-Hung Lai | |||
| Joseph Kahwaji | |||
| Rafael Villicana | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| desensitization | Q2700499 | ||
| P304 | page(s) | 1095-1102 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation | |
| P478 | volume | 89 |
| Q39630785 | 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody |
| Q35008036 | A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation |
| Q50905754 | A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. |
| Q38445336 | Achieving incompatible transplantation through desensitization: current perspectives and future directions |
| Q30277267 | Approach to the Highly Sensitized Kidney Transplant Candidate |
| Q38126085 | B-cell regulation and its application to transplantation |
| Q38175026 | B-cell-mediated strategies to fight chronic allograft rejection |
| Q37820338 | Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach |
| Q41577805 | Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy |
| Q34189435 | Bortezomib in kidney transplantation |
| Q37682802 | Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. |
| Q47574733 | Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies |
| Q37827197 | Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients |
| Q38266375 | Clinical implications of basic science discoveries: janus resurrected--two faces of B cell and plasma cell biology |
| Q41258755 | Combined induction therapy with rabbit antithymocyte globulin and rituximab in highly sensitized renal recipients |
| Q37834028 | Current immunosuppressive treatment after kidney transplantation |
| Q39118422 | Desensitization Protocol in Recipients of Deceased Kidney Donor With Donor-Specific Antibody-Low Titers |
| Q36566858 | Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation |
| Q36586705 | Desensitization combined with paired exchange leads to successful transplantation in highly sensitized kidney transplant recipients: strategy and report of five cases. |
| Q26863564 | Desensitization for solid organ and hematopoietic stem cell transplantation |
| Q38195324 | Desensitization in kidney transplantation: review and future perspectives |
| Q30397952 | Desensitization: Overcoming the Immunologic Barriers to Transplantation |
| Q42635142 | Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation |
| Q40815282 | Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations |
| Q93088300 | Effect of Calculated Panel Reactive Antibody Value on Waitlist Outcomes for Lung Transplant Candidates |
| Q52888455 | Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation. |
| Q36053023 | Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates |
| Q85485720 | Effects of mycophenolic acid on highly sensitized patients awaiting kidney transplant |
| Q43436078 | Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients |
| Q57216622 | Factors Associated With Waiting Time to Deceased Donor Kidney Transplantation in Transplant Candidates |
| Q48703208 | Feasibility, reproducibility, risks and benefits of face transplantation: a prospective study of outcomes |
| Q38269416 | Four years of experience with the Australian kidney paired donation programme |
| Q85040459 | Glomerular diseases and transplantation: similarities in pathogenetic mechanisms and treatment options |
| Q48112929 | Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner. |
| Q40607435 | Humoral immunity in phenotypes of chronic lung allograft dysfunction: A broncho-alveolar lavage fluid analysis |
| Q82599532 | IFNγ production by NK cells from HLA-sensitized patients after in vitro exposure to allo-antigens |
| Q51028676 | Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. |
| Q37778273 | Immunosuppression in the sensitized heart transplant recipient |
| Q37652611 | Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q42243081 | Impact of flow cytometry crossmatch B-cell positivity on living renal transplantation |
| Q58737637 | Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014 |
| Q39118428 | Implementation of a National Priority Allocation System for Hypersensitized Patients in Spain, Based on Virtual Crossmatch: Initial Results. |
| Q50983859 | In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. |
| Q38036246 | Incompatible kidney transplantation: a brief overview of the past, present and future. |
| Q35664634 | Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin |
| Q38258064 | Kidney paired donation: principles, protocols and programs |
| Q39173951 | Kidney paired exchange and desensitization: Strategies to transplant the difficult to match kidney patients with living donors |
| Q87599320 | Kidney transplantation across a positive crossmatch: a single-center experience |
| Q57224820 | Kidney transplantation after desensitization in sensitized patients: a Korean National Audit |
| Q38455229 | Kidney transplantation in highly sensitized patients |
| Q45256335 | Kidney transplantation in immunologically high-risk patients |
| Q37782262 | Malignancy after renal transplantation: the role of immunosuppression |
| Q45008126 | Management of patients on the waiting list for deceased donor kidney transplantation |
| Q27010224 | Modern approaches to incompatible kidney transplantation |
| Q43069832 | Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction |
| Q39534801 | Non-human leukocyte antigen antibodies reactive with endothelial cells could be involved in early loss of renal allografts. |
| Q36865787 | Novel functions of B cells in transplantation |
| Q46185349 | Outcomes of Highly Sensitized Patients Undergoing Simultaneous Liver and Kidney Transplantation: A Single-Center Experience With Desensitization |
| Q45736192 | Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody |
| Q39730031 | Progress in Desensitization of the Highly HLA Sensitized Patient |
| Q83426716 | Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation |
| Q48162992 | Regulatory B cells: the cutting edge of immune tolerance in kidney transplantation |
| Q92574914 | Renal Transplantation in High Immunological Risk Patients: A Single-Center Experience |
| Q39485911 | Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study |
| Q48655730 | Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients |
| Q27026434 | Rituximab in renal transplantation |
| Q40586736 | Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients |
| Q92469286 | Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial |
| Q40523283 | Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab |
| Q35022239 | Strategies to increase the donor pool and access to kidney transplantation: an international perspective |
| Q49332019 | Successful Desensitization of T cell Flow Cytometry Crossmatch Positive Renal Transplant Recipients Using Plasmapheresis and Super High-Dose Intravenous Immunoglobulin. |
| Q33697397 | Successful Renal Transplantation Across HLA Barrier: Report from India |
| Q37888770 | Targeting B cells and antibody in transplantation |
| Q50950214 | The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates. |
| Q34106158 | The generation and maintenance of serum alloantibody. |
| Q38003049 | The impact of donor-specific anti-HLA antibodies on late kidney allograft failure |
| Q38258153 | The increasing clinical importance of alloantibodies in kidney transplantation |
| Q36563918 | The paradoxical functions of B cells and antibodies in transplantation |
| Q41150961 | The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation |
| Q30455087 | The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends |
| Q30454250 | Therapeutic apheresis before and after kidney transplantation |
| Q38118112 | Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. |
| Q85230994 | Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly Human Leukocyte Antigen-Sensitized Patients Awaiting Kidney Transplantation |
| Q33396236 | Use of monoclonal antibodies in renal transplantation |
Search more.